Get the Stockscreener App
11.21
10.96%
-1.38
Q 32 Bio Inc stock is traded at $11.21, with a volume of 2.86M.
It is down -10.96% in the last 24 hours and down -12.90% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
See More
Previous Close:
$12.59
Open:
$12.38
24h Volume:
2.86M
Relative Volume:
3.78
Market Cap:
$190.08M
Revenue:
$53.74M
Net Income/Loss:
$33.24M
P/E Ratio:
4.2092
EPS:
2.6632
Net Cash Flow:
$-27.40M
1W Performance:
-14.36%
1M Performance:
-12.90%
6M Performance:
+211.39%
1Y Performance:
+237.65%
1-Day Range:
$10.81
$12.48
1-Week Range:
$10.81
$14.43
52-Week Range:
$1.5685
$15.02
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
11.21 | 213.48M | 53.74M | 33.24M | -27.40M | 2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | H.C. Wainwright | Buy |
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Q32 Bio Inc. (QTTB) gains Boxer Capital group as 13.3% shareholder - Stock Titan
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 - Yahoo Finance
Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell 3000E Growth Benchmark - marketscreener.com
Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell Microcap Index - marketscreener.com
Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell 3000E Index - marketscreener.com
Q32 Bio Inc.(NasdaqCM: QTTB) added to Russell 3000E Value Benchmark - marketscreener.com
DB0 Forecast — Price Target — Prediction for 2027 - TradingView
Q32 Bio Inc Actuals & Estimates (MUN:DB0) - TradingView
Q32 Bio Inc Actuals & Estimates (NASDAQ:QTTB) - TradingView
Q32 Bio Inc Actuals & Estimates (BOATS:QTTB) - TradingView
Form S-3 Q32 Bio Inc For: 25 June By Investing.com - Investing.com Nigeria
Q32 Bio Files $300 Million Mixed Shelf - marketscreener.com
Q32 Bio (NASDAQ: QTTB) files $300M shelf; May 26 $55M placement noted - Stock Titan
Price to sales forward of Q32 Bio Inc. – NASDAQ:QTTB - TradingView
QTTB Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Q32 Bio Inc. – NASDAQ:QTTB - TradingView
Enterprise value to EBIT forward of Q32 Bio Inc. – NASDAQ:QTTB - TradingView
Enterprise value to revenue forward of Q32 Bio Inc. – NASDAQ:QTTB - TradingView
Q32 Bio Inc (QTTB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why is Q32 Bio stock gaining Friday? - MSN
Q32 Bio Inc (QTTB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Q32 Bio Shareholders Back Directors, Auditor and Executive Pay - The Globe and Mail
Q32 Bio Inc (QTTB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Q32 Bio Inc (QTTB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Q32 Bio Inc (QTTB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Q32 Bio Inc (QTTB) Institutional Confidence - TradingKey
Q32 Bio Inc (QTTB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Director Kathleen LaPorte receives 9,810 Q32 Bio (QTTB) stock options - Stock Titan
Director Mark Iwicki of Q32 Bio (QTTB) awarded 9,810 options at $12.64 strike - Stock Titan
Director Isaac Manke receives 9,810 Q32 Bio (QTTB) stock options at $12.64 strike - Stock Titan
Q32 Bio (QTTB) director awarded 9,810 stock options at $12.64 strike - Stock Titan
Director at Q32 Bio (QTTB) receives 9,810 stock options tied to Atlas Venture - Stock Titan
Director Mary Thistle receives 9,810 Q32 Bio (QTTB) stock options at $12.64 - Stock Titan
Q32 Bio (QTTB) director gets 9,810 options at $12.64, benefits to OrbiMed - Stock Titan
Director at Q32 Bio (NASDAQ: QTTB) receives 9,810 stock options grant - Stock Titan
Q32 Bio Inc (QTTB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Q32 Bio Inc (QTTB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Q32 Bio Inc. (QTTB) Edges Lower, Consolidating Above Key Support LevelInstitutional Volume - newsline.com
QTTB: All proposals, including director elections and audit firm ratification, were approved - TradingView
QTTB News | Q32 BIO INC (NASDAQ:QTTB) - ChartMill
Atlas Venture fund discloses 625,000 Q32 Bio (QTTB) common shares held - Stock Titan
Q32 Bio Raises $55 Million in Private Placement - Global Legal Chronicle
ORBIMED ADVISORS LLC's Strategic Acquisition in Q32 Bio Inc - GuruFocus
Biotechnology Value Fund (QTTB) group reports 2.37M-share position, 150k warrants - Stock Titan
RA Capital affiliates disclose 2.33M-share stake in Q32 Bio (QTTB) - Stock Titan
Q32 Bio Inc. (QTTB) Tumbles 7% as Shares Nears Key Support ZoneContinuation Pattern Picks - newsline.com
Q32 Bio Inc. Stock (QTTB) Opinions on Massive Price Surge - Moomoo
Monday’s insider activity: Q32 Bio and Outlook see major buys By Investing.com - Investing.com South Africa
Q 32 Bio Inc Stock (QTTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):